{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:20:28Z","timestamp":1792106428789,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40266-025-01253-x","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:34:10Z","timestamp":1759484050000},"page":"1103-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer\u2019s Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers"],"prefix":"10.1007","volume":"42","author":[{"given":"Curtis P.","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-7893","authenticated-orcid":false,"given":"Amy","family":"Kovacik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Helman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"1253_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2024.1399121","volume":"15","author":"AY Kim","year":"2024","unstructured":"Kim AY, Al Jerdi S, MacDonald R, Triggle CR. Alzheimer\u2019s disease and its treatment-yesterday, today, and tomorrow. Front Pharmacol. 2024;15:1\u201330.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1253_CR2","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"Alzheimer's Association","year":"2024","unstructured":"Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1253_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13311-021-01146-y","volume":"19","author":"JA Trejo-Lopez","year":"2022","unstructured":"Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer\u2019s disease. Neurotherapeutics. 2022;19(1):173\u201385.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"1253_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230009","volume":"43","author":"A Agarwal","year":"2023","unstructured":"Agarwal A, Gupta V, Brahmbhatt P, Desai A, Vibhute P, Joseph-Mathurin N, et al. Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-\u03b2 therapy. Radiographics. 2023;43(9):e230009.","journal-title":"Radiographics"},{"issue":"4","key":"1253_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","volume":"20","author":"G Yadollahikhales","year":"2023","unstructured":"Yadollahikhales G, Rojas JC. Anti-amyloid immunotherapies for Alzheimer\u2019s disease: a 2023 clinical update. Neurotherapeutics. 2023;20(4):914\u201331.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"1253_CR6","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR Jr., Poussaint TY, et al. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022;43(9):E19\u201335.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13195-023-01321-7","volume":"15","author":"JL Cummings","year":"2023","unstructured":"Cummings JL, Gonzalez MI, Pritchard MC, May PC, Toledo-Sherman LM, Harris GA. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res Ther. 2023;15(1):168.","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"1253_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2214\/AJR.22.28461","volume":"220","author":"M Roytman","year":"2023","unstructured":"Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, et al. Amyloid-related imaging abnormalities: an update. AJR Am J Roentgenol. 2023;220(4):562\u201374.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"1253_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"1253_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"1253_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"1253_CR12","unstructured":"Eli Lilly and Company. KISUNLA (donanemab-azbt) injection, for intravenous use [prescribing information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf. Accessed 18 Aug 2025."},{"key":"1253_CR13","unstructured":"Eisai Inc. LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous use [prescribing information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf. Accessed 18 Aug 2025."},{"issue":"4","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1253_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9(2):211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"1253_CR16","unstructured":"FDA. Guidance for industry: Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products\u2014content and format. 2011."},{"issue":"11","key":"1253_CR17","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324.","journal-title":"Brain"},{"issue":"10","key":"1253_CR18","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2013;34(10):1958\u201365.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1253_CR19","unstructured":"Eisai Inc. LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous use [medication guide]. Available from: https:\/\/www.leqembi.com\/-\/media\/Files\/Leqembi\/Medication-Guide.pdf?hash=d4e8f584-6cf3-41c4-a7f3-34bda6abb800. Accessed 18 Aug 2025."},{"key":"1253_CR20","unstructured":"Eli Lilly and Company. KISUNLA (donanemab-azbt) injection, for intravenous use [medication guide]. Available from: https:\/\/pi.lilly.com\/us\/kisunla-us-mg.pdf?s=mg. Accessed 18 Aug 2025."},{"issue":"11","key":"1253_CR21","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.1002\/alz.14199","volume":"20","author":"DM Rentz","year":"2024","unstructured":"Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, et al. Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer\u2019s disease: navigating clinician-patient engagement. Alzheimers Dement. 2024;20(11):8162\u201371.","journal-title":"Alzheimers Dement"},{"key":"1253_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2024.1412006","volume":"16","author":"KE Foley","year":"2024","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE \u03b54 on A\u03b2 immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1\u20136.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1253_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","volume":"12","author":"BR Troutwine","year":"2022","unstructured":"Troutwine BR, Hamid L, Lysaker CR, Strope TA, Wilkins HM. Apolipoprotein E and Alzheimer\u2019s disease. Acta Pharm Sin B. 2022;12(2):496\u2013510.","journal-title":"Acta Pharm Sin B"},{"key":"1253_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"27","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;27:100150.","journal-title":"J Prev Alzheimers Dis."},{"issue":"5","key":"1253_CR25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward. Neuron. 2019;101(5):820\u201338.","journal-title":"Neuron"},{"issue":"1245","key":"1253_CR26","first-page":"1","volume":"13","author":"PA Bilodeau","year":"2024","unstructured":"Bilodeau PA, Dickson JR, Kozberg MG. The impact of anti-amyloid immunotherapies on stroke care. J Clin Med. 2024;13(1245):1\u201316.","journal-title":"J Clin Med"},{"issue":"1","key":"1253_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","volume":"53","author":"L Sveikata","year":"2022","unstructured":"Sveikata L, Charidimou A, Viswanathan A. Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab. Stroke. 2022;53(1):298\u2013302.","journal-title":"Stroke"},{"issue":"8","key":"1253_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, et al. The boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714\u201325.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1253_CR29","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B, Flanagan ME, Sugg E, Tang M, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388(5):478\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"1253_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501\u201314.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1253_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000333286","volume":"67","author":"A Forster","year":"2012","unstructured":"Forster A, Gass A, Kern R, Ay H, Chatzikonstantinou A, Hennerici MG, et al. Brain imaging in patients with transient ischemic attack: a comparison of computed tomography and magnetic resonance imaging. Eur Neurol. 2012;67(3):136\u201341.","journal-title":"Eur Neurol"},{"key":"1253_CR32","unstructured":"American Society of Neuroradiology. Amyloid-related imaging abnormalities (ARIA) with emerging Alzheimer\u2019s disease therapeutics: Detection and reporting recommendations for clinical practice. Recommended reporting templates. 2023 [cited; Available from: https:\/\/www.asnr.org\/wp-content\/uploads\/2023\/07\/AJNR_ARIA_white_paper_templates_20230713.pdf."},{"issue":"2","key":"1253_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55800","volume":"7","author":"DM Sima","year":"2024","unstructured":"Sima DM, Phan TV, Van Eyndhoven S, Vercruyssen S, Magalhaes R, Liseune A, et al. Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities. JAMA Netw Open. 2024;7(2):e2355800.","journal-title":"JAMA Netw Open"},{"key":"1253_CR34","unstructured":"Wang H, Monkul Nery ES, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, et al. The effect of different donanemab dosing regimens on aria-e and amyloid lowering in adults with early symptomatic Alzheimer\u2019s disease: primary outcome results from TRAILBLAZER-ALZ 6. In: 17th Clinical Trials on Alzheimer\u2019s Disease Conference; 2024; Madrid (Spain); 2024."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01253-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:07:32Z","timestamp":1764252452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01253-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01253-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CPS has received research support from Eli Lilly and Company, Roche, and Genentech; has received speaking fees from Eli Lilly and Company, Eisai, and Roche; and has served as an advisor to Eli Lilly and Company and Eisai. AK, JB, and JH are employees and shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception and design of this review, drafted and\/or critically revised the work, read and approved the final submitted manuscript, and agreed to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}